## IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

| JAZZ PHARMACEUTICALS, INC., )   |                       |
|---------------------------------|-----------------------|
| )<br>Plaintiff, )               |                       |
| v. )                            | C.A. No. 21-691 (GBW) |
| AVADEL CNS PHARMACEUTICALS LLC, |                       |
| )<br>Defendant.                 |                       |

## STIPULATION AND [PROPOSED] ORDER DISMISSING JAZZ'S '963 PATENT INFRINGEMENT CLAIM AGAINST AVADEL AND AVADEL'S NONINFRINGEMENT & INVALIDITY COUNTERCLAIMS <u>AGAINST THE '963 PATENT</u>

Pursuant to Federal Rule of Civil Procedure 41, Jazz Pharmaceuticals, Inc. ("Jazz") and Avadel CNS Pharmaceuticals, LLC ("Avadel") hereby stipulate as follows:

WHEREAS Jazz has sued Avadel in this action ("Action") for infringement of, *inter alia*, Jazz's U.S. Patent No. 8,731,963 (the "'963 patent") (D.I. 1) in connection with Avadel's submission to the United States Food and Drug Administration ("FDA") of New Drug Application ("NDA") No. 214755 seeking FDA approval to market a sodium oxybate drug product ("Avadel's NDA Product");

WHEREAS Avadel filed counterclaims in the Action for noninfringement and invalidity of the '963 patent (D.I. 11);

The parties, by and through their respective undersigned counsel in the Action, and subject to the approval of the Court, stipulate and agree as follows:

1. Pursuant to Fed. R. Civ. P. 41(a)(2), Jazz hereby dismisses without prejudice its claim that Avadel's NDA Product described in Avadel's NDA No. 214755 infringes the '963 patent in this Action.

2. Pursuant to Fed. R. Civ. P. 41(a)(2) and 41(c), Avadel hereby dismisses without

prejudice its counterclaims for noninfringement and invalidity against the '963 patent in this Action.

3. Nothing herein shall prevent the parties from seeking or obtaining other relief in the Action, including with respect to the other patents-in-suit in the Action, which remain pending and are not affected by this Stipulation.

Dated: March 6, 2023

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Jeremy A. Tigan

Jack B. Blumenfeld (#1014) Jeremy A. Tigan (#5239) 1201 North Market Street P.O. Box 1347 Wilmington, DE 19899 (302) 658-9200 jblumenfeld@morrisnichols.com jtigan@morrisnichols.com

OF COUNSEL:

F. Dominic Cerrito Eric C. Stops Evangeline Shih Andrew S. Chalson Gabriel P. Brier Frank C. Calvosa QUINN EMANUEL URQUHART & SULLIVAN, LLP 51 Madison Avenue, 22nd Floor New York, NY 10010 (212) 849-7000

Attorneys for Plaintiff Jazz Pharmaceuticals, Inc. MCCARTER & ENGLISH, LLP

/s/ Alexandra M. Joyce

Daniel M. Silver (#4758) Alexandra M. Joyce (#6423) Renaissance Centre 405 N. King St., 8<sup>th</sup> Floor Wilmington, DE 19801 (302) 984-6300 dsilver@mccarter.com ajoyce@mccarter.com

OF COUNSEL:

Daralyn J. Durie MORRISON & FOERSTER LLP 425 Market Street San Francisco, CA 94105 (415) 568-6034

Kira A. Davis Katherine E. McNutt MORRISON & FOERSTER LLP 707 Wilshire Boulevard Los Angeles, CA 90017 (213) 892-5200

Kenneth G. Schuler Marc N. Zubick Alex M. Grabowski Sarah W. Wang LATHAM & WATKINS LLP 330 North Wabash Avenue, Suite 2800 Chicago, IL 60611 (312) 876-7700

Sarah Propst LATHAM & WATKINS LLP 555 Eleventh Street, NW, Suite 1000 Washington, D.C. 20004-1304 (202) 637-1076

Herman Yue LATHAM & WATKINS LLP 1271 Avenue of the Americas New York, NY 10020 (212) 906-1200

Attorneys for Defendant Avadel CNS Pharmaceuticals, LLC

**SO ORDERED** this \_\_\_\_\_ day of March, 2023.

United States District Court Judge